U
NAVB

UBS’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

UBS’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-3,415
Closed -$181K – 10974
2013
Q3 		$181K Buy
3,415
+900
+36% +$52.5K ﹤0.01% 5303
2013
Q2 		$134K Buy
+2,515
New +$126K ﹤0.01% 5543

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS's NAVB Position: Q3 2014 in Review

UBS increased its Navidea Biopharmaceuticals Inc. (NAVB) stake by 19% in Q3 2014, buying an estimated $5.69K and bringing the position to 1,370 shares worth $36K. The position accounts for ﹤0.01% of the portfolio, ranked #7243.

UBS first reported a position in NAVB in Q2 2013 and has held it in 6 quarters since. The position peaked at $221K in Q3 2013. 81 funds tracked by Wall St. Rank hold NAVB as of Q3 2014.

  • UBS held 1,370 shares of Navidea Biopharmaceuticals Inc. worth $36K as of Q3 2014.
  • UBS bought 215 Navidea Biopharmaceuticals Inc. shares in Q3 2014, an estimated $5.69K.
  • Navidea Biopharmaceuticals Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7243 holding.
  • UBS first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and has held it in 6 quarters since.
  • UBS's Navidea Biopharmaceuticals Inc. position peaked at $221K in Q3 2013.
  • 81 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.